{"id":"W2922151518","doi":"10.1200/jco.2019.37.7_suppl.tps340","title":"PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Olaparib; Prostate cancer; Internal medicine; Clinical endpoint; Population; Oncology; Prednisone; Enzalutamide; Placebo; Hazard ratio; Cancer; Urology; Randomized controlled trial; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639979,0.001537306,0.001811765,0.0005468787,0.000319498,0.001115805,0.001100969,0.001317848,0.008617964],"category_scores_gemma":[0.002048122,0.0005881514,0.001521355,0.0004987897,0.0008838927,0.0009420669,0.0006586165,0.003214276,0.001186816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007110419,"about_ca_system_score_gemma":0.001293686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000617758,"about_ca_topic_score_gemma":0.001662626,"domain_scores_codex":[0.9995269,0.000274029,0.00001925195,0.00007154837,0.00004639015,0.0000619202],"domain_scores_gemma":[0.9989428,0.0002695175,0.0002770298,0.00005201291,0.00005839965,0.0004003101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9663173,0.005564692,0.0008039096,0.0009073871,0.001173119,0.0001235618,0.00004588498,0.0005595066,0.00324719,0.0001534713,0.001950955,0.01915311],"study_design_scores_gemma":[0.9590471,0.03828628,0.0007483264,0.00002985306,0.0003519533,0.00006749489,0.00001426516,0.0002005344,0.0002452567,0.0001110392,0.0008898944,0.000008019623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9623994,0.01222256,0.001591913,0.002573011,0.001075219,0.009441754,0.005329374,0.0003550303,0.005011727],"genre_scores_gemma":[0.9638036,0.005977747,0.003482937,0.002757247,0.0006101916,0.01034559,0.006133615,0.00005734872,0.006831777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008617964,"threshold_uncertainty_score":0.02882999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1085859277782993,"score_gpt":0.4756403416663116,"score_spread":0.3670544138880123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}